Business & Regulation

Ali Pashazadeh from Treehill Partners offers his advice for navigating the turbulent period and keeping on track for commercial success.

From renewable energy to bicycle schemes and more; here are just a few examples of how a pharma business can be more sustainable.

The details and reactions behind a recent FDA investigation into the cancer-risk of CAR-T therapies

Experts from the Access to Medicine Foundation discuss how to reduce the risk of antimicrobial resistance (AMR) in antibiotic manufacturing.

How do we encourage the development of new cell and gene therapies without compromising our ethics?

The Medicine Maker’s all-inclusive advent calendar…

Countries that struggled to acquire COVID-19 vaccines have not forgotten the inequity, and are reminding pharma giants that they shouldn’t either

A deep dive into the dangers of fentanyl entering the US supply chain – and the importance of the Drug Supply Chain Security Act

What can the pharma industry do about the glass ceiling in women’s careers?

Exploring the role of AI in helping bring more medicines to market.